Dr. Matthew Christiansen, state health officer and commissioner, says the data is helping the state plan ahead in anticipation of new drinking water standards.
According to a news release from the West Virginia Department of Health and Human Resources, over two dozen public water systems in West Virginia have detectable levels of so-called "forever chemicals."
The primary Senate sponsors of S.B.543 are Oregon State Senators Janeen Sollman and Michael Dembrow. The primary House sponsors are Oregon State Representatives Maxine Dexter and Tom Andersen.
Pilot study demonstrates treating PFAS with CAC at the air-water interface eliminates PFAS mass flux into groundwater — halting further plume development.
In Situ Remediation Services Ltd. (IRSL), a leading environmental remediation company based in Canada, has recently completed a pilot study demonstrating how PFAS are effectively treated in the capillary fringe of an AFFF source zone by in situ injection using Colloidal Activated Carbon (CAC).
Webinar: Remediation Technology sits down with Brian Pinkard of Aquagga and Maureen Dooley of Regenesis to discuss options for destroying PFAS from AFFF firefighting foam.
Webinar: PFAS destruction products are increasingly commercially available, with technologies like Aquagga’s hydrothermal alkaline treatment, or HALT, and Regenesis’s PlumeStop, an in-situ colloidal activated carbon, or CAC.
Five of the compounds detected have never before been reported in groundwater anywhere in the world. They're not per and polyfluoroalkyl substances (PFAS).
Despite a massive focus on PFAS substances and pesticide residues in Danish drinking water, little attention is paid to the hundreds of other chemical compounds in our groundwater.
Aquagga, Inc., a Tacoma, Washington-based Public Benefit Corporation, has entered into an exclusive licensing agreement with Mines for the commercialization of the HALT-PFAS technology.
"They're saying, 'Hey, doctors, if you're treating patients who live in PFAS-contaminated areas, you need to do more for these patients,'" said Jamie DeWitt, an immunotoxicologist at East Carolina University.